Current Allergy and Clinical Immunology - March 2008

More documents

Recommendations

Info

$latex allerGy revisited : a review - Allergy Society of South Africa$

$Cross-reactivity of food allegens with latex - ALLSA$

PRODUCT NEWSMSD (Pty) Ltd is proud to announce the introduction ofSINGULAIR 4 mg. Studies have shown that asthma in childrenunder the age of six is on the increase worldwide. 1SINGULAIR 4 mg is the first asthma controller therapy, thatis not a steroid, to be approved in South Africa for childrenas young as 2 years old. 2Studies have shown improvements in symptom and activityscores from as early as day one, affirming the efficacy ofSINGULAIR 4 mg in this age group. 3 The current guidelinesfor treatment of asthma in children, as compiled by theAllergy Society of South Africa (ALLSA), call for the introductionof a leukotriene antagonist as a controller agent inthis age group at step 2, after the use of short-acting relievermedication has proven to be inadequate in controllingasthma symptoms. In other words using leukotriene antagonistas a first line controller agent. 4 At present, of theleukotriene receptor antagonists, only SINGULAIR is indicatedfor use in children under the age of 12. 2SINGULAIR 4 mg is indicated for the prophylactic treatmentof mild to moderate asthma in the 2-5 year old age group.SINGULAIR 4 mg is presented in a 28-day pack and onetablet should be taken once daily at bedtime. 2 To date worldwideuse is more than 2.2 million children in more than 90countries. This puts SINGULAIR in the unique position ofbeing the only controller therapy to be registered and indicatedfor asthmatic patients from 2 years old and up. 2TheFREEDOMtobe a Child!REFERENCES:1 Ehrlich, R. The Prevalence of Asthma in South Africa. CurrentAllergy and Clinical Immunology March 2002; Vol 15: 4-8.2 Data on File.3 Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotrienereceptor antagonist, for the treatment of persistent asthma inchildren aged 2 to 5 years. Pediatrics 2001;108(3):1-10.4 Motala C, Kling S, Gie R, et al. Guidline for the management ofChronic Asthma in Children – 2000 Update. SAMJ. 2000; 90:524-539.MSD (Pty) Ltd (Reg. No. 1996/003791/07), Private Bag 3, HalfwayHouse 1685.Copyright © MERCK & CO., INC., Whitehouse Station, N.J., U.S.A.1999. ® Registered Trademark of MERCK & CO., INC., WhitehouseStation, N.J., U.S.A. Before prescribing, please refer to the full packageinsert. 06-2004-SGA-03-ZA-230-OReg. No: 35/10.2.2/0397, SINGULAIR 4 mg S3Cipla’s Dry Powder RangeStill the most cost-effective 1 combinations available!Feb 2008For Mr. Moderate AsthmaticRx: with DP-Haler l Revolizer1. Budeflam DP 400µg daily2. Foratec DP 12µg daily3. Asthavent 200µg DP PRNDr Make It- BetterREFERENCE1. PCD Feb 2008.S3 Reg. No. 36/21.5.1/0258S2 Reg. No. 37/10.2.1/0084S2 Reg. No. 30/10.2.1/0345Current Allergy & Clinical Immunology, March 2008 Vol 21, No. 1 53
PRODUCT NEWSBOEHRINGER INGELHEIM LAUNCHESTHE NEW INFLAMMIDE ® 200 NOVOLIZER ®The prevalence of asthma is continuing to rise throughoutthe world and South Africa. Guidelines still recommendinhaled corticosteroids as the cornerstone ofasthma therapy. 1 Despite the availability of numeroustreatments the disease remains poorly controlled. 2Inappropriate and incorrect use of inhaler devices contributeto the lack of adequate asthma control; 71% ofpatients misuse their MDIs and up to 47% of patientscannot co- ordinate on activation and inspiration. 3 It isnow well recognised that improvement in drug deliverywill continue to be paramount in improving asthma management.4Boehringer Ingelheim has launched the newInflammide ® 200 Novolizer ® . This product combinesthe proven efficacy of Inflammide ® 200 with the innovativetechnology of the Novolizer ® delivery system.The Inflammide ® 200 Novolizer ® is designed in such away that it is virtually impossible to use incorrectly,closely meeting the characteristics sought in an ‘ideal’inhaler. 5The Inflammide ® 200 Novolizer ® is breath actuated andcan only be successfully activated once the thresholdPIFR of 35-50 litres/min is generated. At this level thecomplete dose is delivered to the patient. The Novolizer ®has a triple feedback that tells the patient when eachdose has been successfully inhaled, 5 thus optimisingdosing.In healthy volunteers the median lung deposition ofbudesonide administered via the Novolizer ® was 19.9 -32.1% at mean PIFR of 45 - 90 litres/min. 6The Inflammide ® 200 Novolizer ® contains 200 µg ofbudesonide per inhalation in a 200-dose cartridge. Theproduct will be available in 2 forms:• The Inflammide ® 200 Novolizer ® Complete whichcontains the Novolizer device and a cartridge.• The Inflammide ® 200 Novolizer ® refill which containsthe cartridge only.In line with the Montreal Protocol manufacturers werecompelled to switch their asthma inhalers, which containCFC propellants, to more environmentally friendly productsby December 2005. The Inflammide ® 200 Novolizer ®is a multidose dry powder inhaler (MDPI) and does notcontain any propellants, making it not only patient-friendlybut environmentally friendly too.The Inflammide ® 200 Novolizer ® offers substantial advantagesover metered dose inhalers making it an idealreplacement product for patients using budesonideMDIs.For further information please contact Greg Zurnamer(Inflammide ® 200 Novolizer ® product manager) at 011-886-1075 or e-mail: zurnamer@jnb.boehringer-ingelheim.comREFERENCES1. Lalloo UG et al. Guidelines for the management of chronic asthmain adults - 2000 update. S Afr Med J 2000;, 90: 540-552.2. Barnes PJ. Editorial Overview. Asthma management: can we furtherimprove compliance and outcomes? Respir Med 2004; supplementA, S8-S9.3. Giraud V, Roche N. Misuse of corticosteroid metered-doseinhaler is associated with decreased asthma stability. Eur RespirJ 2002; 19: 246 251.4. Barnes PJ. Asthma guidelines: recommendations versus reality.Respir Med 2004; Supplement A S1-S7.5. O’Conner BJ. The ideal inhaler: design and characteristics toimprove outcomes. Respir Med 2004; Supplement A S10-S16.6. Newman SP, Hirst PH, Pitcairn GR. Scintigraphic evaluation oflung deposition with a novel inhaler device. Curr Opin Pulm Med2001; 7(suppl 1): S12- S14.ONLINE CPD ACCREDITATION NOWAVAILABLE FOR CURRENT ALLERGY& CLINICAL IMMUNOLOGYCurrent Allergy & Clinical Immunology has beenaccredited for CPD points in the Clinical category,so you can now earn 2 CPD points for IndividualLearning. CPD accreditation is only availablethrough the online service; no faxed or mailedresponses will receive CPD credits. To obtainCPD credits:1. Read the journal2. Answer the questionnaire on p.59 byaccessing the online CPD accreditation on theALLSA website at www.allergysa.org/cpdor follow the links from the home pagewww.allergysa.org.3. To register, you will need to enter your name,personal details, HPCSA number and a password.4. Once you have registered, you will receive anemail confirming your registration. You caneither answer the questionnaire immediatelyor log on at a later date to answer the questionnaire.Please note that each questionnairehas a closing date – the closing date for submissionof the November 2008 questionnaireis 31 March 2008 and for the March 2008questionnaire it is 30 June 2008.5. Follow the instructions given on the questionnairepage and online.6. After you have submitted your answers, theywill be marked immediately, and you will beinformed of the results and the number ofpoints earned.7. At any time you will be able to see your currentCPD credits from the journal by logging on.54 Current Allergy & Clinical Immunology, March 2008 Vol 21, No. 1
Page 6 and 7: with memory T-cell phenotypes. 18 T
Page 8 and 9: Burkholderia cepacia may be serious
Page 10 and 11: Fig. 4. Sweat test.Stage 3Lymphocyt
Page 12 and 13: AN UPDATE OF THE PRIMARY ANTIBODYDI
Page 14 and 15: lymphocytes refine the primary anti
Page 16 and 17: ange of haematological problems occ
Page 19 and 20: SEVERE COMBINED IMMUNODEFICIENCY(SC
Page 21 and 22: tinely from all neonates at birth i
Page 23 and 24: tions to the use of antiviral drugs
Page 25 and 26: therapeutic IVIG are complex. In ma
Page 27 and 28: TABLE III. Recommendations for the
Page 29 and 30: 5. Ballow M. Mechanisms of action o
Page 31 and 32: Fig. 2. Surface epidermis with unde
Page 33 and 34: sone). Unfounded steroidophobia is
Page 35 and 36: tant reaction fades by 72 hours. Fo
Page 37 and 38: try worker: case report and review
Page 39 and 40: ➞Step up if needed (first check i
Page 41 and 42: NEWSALLSA hosts a symposium at the
Page 43: PRODUCT NEWSNEW DESIGN FOR SYMBICOR
Page 47 and 48: PRODUCT NEWSNASONEX IS NOW INDICATE
Page 49 and 50: PRODUCT NEWSNew Nestlé NAN H.A. 1
Page 51: INSTRUCTIONS FOR AUTHORSCurrent All

Current Allergy and Clinical Immunology - March 2008

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?